Does IL 28 B genotyping still have a role in the era of direct‐acting antiviral therapy for chronic hepatitis C infection?

JA Holmes, PV Desmond… - Journal of viral …, 2012 - Wiley Online Library
JA Holmes, PV Desmond, AJ Thompson
Journal of viral hepatitis, 2012Wiley Online Library
IL 28B genotype has been shown to be the strongest pretreatment predictor of sustained
virological response (SVR) in patients with genotype 1 chronic hepatitis C infection (CHC)
treated with pegylated interferon (peg‐IFN) and ribavirin (RBV). Patients carrying the good
response genotype have a two‐to threefold higher chance of SVR than those with a poor
response genotype, manifest as dramatically improved early viral kinetics. However, the
treatment paradigm for CHC is changing with the introduction of potent direct‐acting …
Summary
IL28B genotype has been shown to be the strongest pretreatment predictor of sustained virological response (SVR) in patients with genotype 1 chronic hepatitis C infection (CHC) treated with pegylated interferon (peg‐IFN) and ribavirin (RBV). Patients carrying the good response genotype have a two‐ to threefold higher chance of SVR than those with a poor response genotype, manifest as dramatically improved early viral kinetics. However, the treatment paradigm for CHC is changing with the introduction of potent direct‐acting antivirals (DAAs). IL28B genotype remains relevant to both telaprevir and boceprevir treatment regimens, although the strength of association with virological response is attenuated. The association between IL28B genotype and outcomes of treatment regimens that involve peg‐IFN plus combination DAA therapy, or IFN‐free regimens, is currently being evaluated. IL28B genotype may remain relevant to individualizing the choice of treatment regimen in the future.
Wiley Online Library